LY404039 - CAS 635318-11-5
Catalog number: 635318-11-5
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
LY-404,039, also known as pomaglumetad, is an amino acid analog drug that acts as a highly selective agonist for the metabotropic glutamate receptor group II subtypes mGluR2 and mGluR3.
Publictions citing BOC Sciences Products
  • >> More
GW786034 HCl
1.Role of calcium, glutamate and NMDA in major depression and therapeutic application.
Deutschenbaur L1, Beck J1, Kiyhankhadiv A1, Mühlhauser M1, Borgwardt S1, Walter M1, Hasler G1, Sollberger D1, Lang UE2. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4;64:325-33. doi: 10.1016/j.pnpbp.2015.02.015. Epub 2015 Mar 4.
Major depression is a common, recurrent mental illness that affects millions of people worldwide. Recently, a unique fast neuroprotective and antidepressant treatment effect has been observed by ketamine, which acts via the glutamatergic system. Hence, a steady accumulation of evidence supporting a role for the excitatory amino acid neurotransmitter (EAA) glutamate in the treatment of depression has been observed in the last years. Emerging evidence indicates that N-methyl-D-aspartate (NMDA), group 1 metabotropic glutamate receptor antagonists and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) agonists have antidepressant properties. Indeed, treatment with NMDA receptor antagonists has shown the ability to sprout new synaptic connections and reverse stress-induced neuronal changes. Based on glutamatergic signaling, a number of therapeutic drugs might gain interest in the future. Several compounds such as ketamine, memantine, amantadine, tianeptine, pioglitazone, riluzole, lamotrigine, AZD6765, magnesium, zinc, guanosine, adenosine aniracetam, traxoprodil (CP-101,606), MK-0657, GLYX-13, NRX-1047, Ro25-6981, LY392098, LY341495, D-cycloserine, D-serine, dextromethorphan, sarcosine, scopolamine, pomaglumetad methionil, LY2140023, LY404039, MGS0039, MPEP, 1-aminocyclopropanecarboxylic acid, all of which target this system, have already been brought up, some of them recently.
2.Modulation of mGlu2 Receptors, but Not PDE10A Inhibition Normalizes Pharmacologically-Induced Deviance in Auditory Evoked Potentials and Oscillations in Conscious Rats.
Ahnaou A1, Biermans R1, Drinkenburg WH1. PLoS One. 2016 Jan 25;11(1):e0147365. doi: 10.1371/journal.pone.0147365. eCollection 2016.
Improvement of cognitive impairments represents a high medical need in the development of new antipsychotics. Aberrant EEG gamma oscillations and reductions in the P1/N1 complex peak amplitude of the auditory evoked potential (AEP) are neurophysiological biomarkers for schizophrenia that indicate disruption in sensory information processing. Inhibition of phosphodiesterase (i.e. PDE10A) and activation of metabotropic glutamate receptor (mGluR2) signaling are believed to provide antipsychotic efficacy in schizophrenia, but it is unclear whether this occurs with cognition-enhancing potential. The present study used the auditory paired click paradigm in passive awake Sprague Dawley rats to 1) model disruption of AEP waveforms and oscillations as observed in schizophrenia by peripheral administration of amphetamine and the N-methyl-D-aspartate (NMDA) antagonist phencyclidine (PCP); 2) confirm the potential of the antipsychotics risperidone and olanzapine to attenuate these disruptions; 3) evaluate the potential of mGluR2 agonist LY404039 and PDE10 inhibitor PQ-10 to improve AEP deficits in both the amphetamine and PCP models.
3.Hydrophilic interaction chromatography with aerosol-based detectors (ELSD, CAD, NQAD) for polar compounds lacking a UV chromophore in an intravenous formulation.
Cintrón JM1, Risley DS. J Pharm Biomed Anal. 2013 May 5;78-79:14-8. doi: 10.1016/j.jpba.2013.01.022. Epub 2013 Jan 26.
In this work, a high performance liquid chromatography (HPLC) method is reported for the separation and quantitation of a drug substance that is highly polar and lacking a chromophore in a mannitol intravenous (IV) formulation. Three polar stationary phases operated in hydrophilic interaction chromatography (HILIC) mode were evaluated in conjunction with an Alltech 800 ELSD detector. These columns were evaluated with respect to chromatographic properties such as buffer, pH and organic concentrations to identify the best stationary phase. The chromatographic method was then validated for the determination of mGlu2/3 receptor agonist (-)-(1R, 4S, 5S, 6S)-4-Amino-2-sulfonylbicyclo [3.1.0] hexane-4,6-dicarboxylic acid (LY404039) content in a mannitol IV formulation with respect to linearity (R(2) of 0.9997), repeatability (%RSD of 0.36%), accuracy, solution stability (99.56% after 24h), specificity, intra-assay precision (%RSD 0.48%) and limit of detection (LOD, ∼50 μg/mL).
4.In vitro characterization of the bioconversion of pomaglumetad methionil, a novel metabotropic glutamate 2/3 receptor agonist peptide prodrug.
Moulton RD1, Ruterbories KJ2, Bedwell DW2, Mohutsky MA2. Drug Metab Dispos. 2015 May;43(5):756-61. doi: 10.1124/dmd.114.062893. Epub 2015 Mar 9.
To characterize the hydrolysis of the peptide prodrug pomaglumetad methionil (LY2140023; (1R,4S,5S,6S)-4-(L-methionylamino)-2-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid 2,2-dioxide), to the active drug LY404039 [(1R,4S,5S,6S)-4-amino-2-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid 2,2-dioxide], a series of in vitro studies were performed in various matrices, including human intestinal, liver, kidney homogenate, and human plasma. The studies were performed to determine the tissue(s) and enzyme(s) responsible for the conversion of the prodrug to the active molecule. This could enable an assessment of the risk for drug interactions, an evaluation of pharmacogenomic implications, as well as the development of a Physiologically Based Pharmacokinetic (PBPK) model for formation of the active drug. Of the matrices examined, hydrolysis of pomaglumetad methionil was observed in intestinal and kidney homogenate preparations and plasma, but not in liver homogenate.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related mGluR Products

CAS 1311385-32-6 LY2979165

(CAS: 1311385-32-6)

LY2979165 is a mGlu2 agonist, which is a novel potent agent that is used as anti-depressants.

CAS 97240-79-4 Topiramate

(CAS: 97240-79-4)

Topiramate is a kainate GluR5 receptor antagonist,originally used as an anticonvulsant.

CAS 1445605-23-1 Lu AF21934

Lu AF21934
(CAS: 1445605-23-1)

Lu AF21934 is a selective and brain-penetrating positive allosteric modulator (PAM) of mGlu4 receptors (IC50= 500 nM) on the harmaline-induced tremor and other ...

(CAS: 1623101-11-0)

VU-0483605, an isoindol derivative, has been found to be a mGluR1 positive allosteric modulator and probably be effective against schizophrenia. EC50: 356 and 3...

CAS 635318-11-5 LY404039

(CAS: 635318-11-5)

LY-404,039, also known as pomaglumetad, is an amino acid analog drug that acts as a highly selective agonist for the metabotropic glutamate receptor group II su...

CAS 433967-28-3 VU 0357121

VU 0357121
(CAS: 433967-28-3)

VU0357121 is a novel positive allosteric modulator (PAM) of mGlu5 with EC50 of 33 nM, is inactive or very weakly antagonizing at other mGlu receptor subtypes.

CAS 543906-09-8 Mavoglurant

(CAS: 543906-09-8)

Mavoglurant is a structurally novel, non-competitive mGlu5 receptor antagonist (IC50=30 nM), as a a selective non-competitive antagonist.

(CAS: 1443118-44-2)

ML337 is a Selective negative allosteric modulator of mGlu3 with IC50 value of 593 nM. It shows no activity at mGlu1, mGlu2 or mGlu4-8 at concentrations up to 3...

CAS 872363-17-2 Dipraglurant

(CAS: 872363-17-2)

Dipraglurant is a mGlu5 receptor negative allosteric modulator. It is currently in phase II for the treatment of dyskinesia in Parkinson's disease.

CAS 125404-04-8 TCN238

(CAS: 125404-04-8)

TCN238 is an orally available, brain penetrant and positive allosteric mGlu4 receptor modulator (EC50= 1 μM) with 30-fold selectivity over mGluR5 using human re...

CAS 198419-90-8 (±)-LY 367385

(±)-LY 367385
(CAS: 198419-90-8)

(±)-LY367385 is a selective mGlu1a antagonist.

CAS 2018282-44-3 BMT-145027

(CAS: 2018282-44-3)

BMT-145027 is a potent mGluR5 PAM without inherent agonist activity with an EC50 of 47 nM. BMT-145027 is a non-MPEP site PAM to demonstrate in vivo efficacy.

CAS 1254977-87-1 JNJ-42153605

(CAS: 1254977-87-1)

JNJ-42153605 is a selective positive allosteric modulator of the metabotropic glutamate 2 (mGlu2) receptor (EC50= 17 Nm) with an acceptable pharmacokinetic prof...

CAS 871362-31-1 CTEP

(CAS: 871362-31-1)

CTEP is a novel, long-acting, orally bioavailable allosteric antagonist of mGlu5 receptor (IC50=2.2 nM), showing >1000-fold selectivity over other mGlu receptor...

CAS 1127498-03-6 JNJ-40411813

(CAS: 1127498-03-6)

JNJ-40411813 is a novel positive allosteric modulator of the metabotropic Glutamate 2 receptor (mGlu2R) with EC50 of 147 nM.

CAS 1186195-60-7 MTEP hydrochloride

MTEP hydrochloride
(CAS: 1186195-60-7)

Glutamate, the major excitatory neurotransmitter in the brain, acts on both ionotropic and metabotropic glutamate receptors. Excessive metabotropic glutamate re...

CAS 757950-09-7 Raseglurant

(CAS: 757950-09-7)

Raseglurant is a negative allosteric modulator of the mGlu5 receptor and derivative of MPEP. It can be used for the treatment of migraine, gastroesophageal refl...

CAS 96206-92-7 MPEP

(CAS: 96206-92-7)

MPEP is a selective mGlu5 receptor antagonist with IC50 of 36 nM, exhibiting no appreciable activity at mGlu1b/2/3/4a/7b/8a/6 receptors.

CAS 693288-97-0 CPPHA

(CAS: 693288-97-0)

CPPHA is a selective positive allosteric modulator of mGluR5 receptor. It is thought to act at a novel allosteric site and potentiates mGlu5 responses by a mech...

CAS 1246086-78-1 VU 0364439

VU 0364439
(CAS: 1246086-78-1)

Chemical Structure

CAS 635318-11-5 LY404039

Quick Inquiry

Verification code

Featured Items